Clinical trials: Hepatitis C, completed
Hepatitis C, HIV
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia
Hepatitis C (HCV) is an important global public health problem, disproportionately affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is…
- Trial name
- HCV-Epi (NCT02361541)
- Testing
- HCV screening
- Where
- Cambodia
- Volunteers
- 3,045 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and to evaluate the safety and tolerability of LDV/SOF FDC and sofosbuvir…
- Trial name
- NCT02738333
- Testing
- LDV/SOF, SOF, RBV
- Where
- 37 sites in Japan
- Volunteers
- 239 people
- Sponsor
- Gilead Sciences
Hepatitis C
Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab combined with ribavirin for initial treatment of chronic HCV genotype 1 infection.
- Trial name
- NCT01273948
- Testing
- Bavituximab, Pegylated interferon (PEG-IFN)
- Where
- Georgia
- Volunteers
- 66 people
- Sponsor
- Peregrine Pharmaceuticals
Breast Cancer, Hepatitis C
Association of Hepatitis C Virus With Breast Cancer
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection.
- Trial name
- NCT04090164
- Where
- Egypt
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Chronic HCV Infection
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
- Trial name
- NCT05395416
- Testing
- HEC74647PA+HEC110114
- Where
- 36 sites in China
- Volunteers
- 514 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs.
- Trial name
- NCT00367887
- Testing
- Peg-Intron, REBETOL, HCV 796
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Hepatitis C
Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients
Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C
- Trial name
- NCT00146016
- Testing
- Amantadine
- Where
- Netherlands
- Volunteers
- 390 people
- Sponsor
- UMC Utrecht
Hepatitis C
Fluvastatin Versus Hepatitis C Virus
This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.
- Trial name
- NCT00441493
- Testing
- fluvastatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bader, Ted, M.D.
Hepatitis C
A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects
This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals
- Trial name
- NCT02760758
- Testing
- CDI-31244
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
Hepatitis C, Human Immunodeficiency Virus
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV).
- Trial name
- NCT02650024
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Hepatitis C, Chronic
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
The current trial is designed to prospectively explore the safety of erythropoietin use for the treatment of anemia during boceprevir plus peginterferon alfa-2b/Ribavirin (PEG2b/RBV) therapy and to assess its relationship to…
- Trial name
- NCT01023035
- Testing
- Boceprevir, Peginterferon alfa-2b (PEG2b), Ribavirin (RBV)
- Volunteers
- 687 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Drug Interaction Oral Contraceptive Pill (OCP)
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
- Trial name
- NCT01063023
- Testing
- Ortho Tri-Cyclen®, BMS-650032
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
This 2-arm study will compare the efficacy and safety of treatment with Pegasys (180 µg weekly) plus Copegus (800 mg daily) and Pegasys (180 µg weekly) plus Copegus (1000-1200 mg daily) in interferon-naive patients with CHC…
- Trial name
- NCT00353418
- Testing
- Peginterferon alfa-2a, Ribavirin
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
Study P02538 Part 2 is a 5-year long term follow-up (LTFU) study in pediatric participants who were treated with at least one dose of peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) and who completed the follow-up in the…
- Trial name
- NCT00761735
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C
This open-label, multicenter, treatment response guided study will evaluate the sustained virological response and safety of the triple combination therapy boceprevir, Pegasys (peginterferon alfa-2a) and Copegus (Ribavirin) in…
- Trial name
- NCT01591460
- Testing
- boceprevir, peginterferon alfa-2a [Pegasys], ribavirin (Copegus]
- Where
- 32 sites in Austria, Germany and 4 more
- Volunteers
- 165 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously…
- Trial name
- POLARIS-1 (NCT02607735)
- Testing
- SOF/VEL/VOX
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 416 people
- Sponsor
- Gilead Sciences
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.